MAPT and Alzheimer disease: LATE-like hypometabolic pattern in aMCI can identify a subgroup of subjects distinct from AD and controls in terms of clinical severity, medial temporal atrophy, cortical tau load, and cognitive decline, supporting the utility of 18F-FDG-PET as a biomarker that provides inferential support for the specific detection of LATE.